Extrapulmonary neuroendocrine carcinoma of unknown primary origin gives a median survival of two and a half months.1

Only 42% of patients ever reach second line therapy, and 18% a third.2

A target that works in one neuroendocrine cancer ought to be made to work in all of them.

Please note: Orvexa Pharma operates in a stealth capacity.

Someone on the team reads every message. Details are held only so that we can answer. Privacy statement.